The early benefit assessment under Paragraf 35a SGB V is the German procedure for evaluating the additional benefit of reimbursable medicinal products with new active substances after their market entry. The Federal Joint Committee (G-BA) assesses the benefit against a defined appropriate comparator therapy. The resolution forms the basis for the reimbursement amount negotiation within statutory health insurance.
Dossier and Assessment Mandate
The pharmaceutical company submits the legally required evidence in the form of a dossier. This includes the approved indications, medical benefit, additional benefit compared with the comparator therapy, affected patient groups, therapy costs, and requirements for quality-assured use. The G-BA may conduct the assessment itself or commission IQWiG or third parties to do so. The Rules of Procedure and the Ordinance on the Benefit Assessment of Medicinal Products (AM-NutzenV) specify the required form of evidence.
The focus is not simply on listing positive study results. The data are evaluated for the population and comparator therapy defined by the G-BA. The process comprises dossier submission, the published benefit assessment, a written and oral commenting procedure, and the resolution. In the resolution, the G-BA sets out, among other things, the extent of the additional benefit, the affected patient groups, the requirements for quality-assured use, and the therapy costs.
Additional Benefit as the Core Decision
Additional benefit is a comparative concept: it asks whether the new medicinal product offers an advantage or disadvantage over the appropriate comparator therapy with regard to relevant patient parameters. The assessment outcome may differ across subpopulations where studies or the care situation support such distinctions. In addition to mortality and morbidity, health-related quality of life and adverse effects are also considered patient-relevant outcomes.
A joint clinical assessment report prepared at EU level may be taken into account in the German procedure, provided that the data addressed therein are suitable for the country-specific question. This does not supersede the German assessment: the G-BA continues to decide on additional benefit and the relevant comparator therapy under German law. This interplay requires a traceable mapping of the same study data to different assessment questions.
Distinction: Marketing Authorization and Price Decision
The early benefit assessment takes place after marketing authorization and is not a renewed review of whether a medicinal product is sufficiently effective and safe to be placed on the market. This benefit-risk assessment is part of the marketing authorization procedure and is covered in the existing entry on marketing authorization. Paragraf 35a SGB V instead asks about the additional patient-relevant benefit compared with care without the new medicinal product.
Nor does the resolution itself set the final price. It provides the assessment basis for negotiating a reimbursement amount between the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) and the company. The procedure therefore differs both from marketing authorization and from a direct price-setting mechanism, even though its outcome has significant economic implications for reimbursement.
The early benefit assessment is thus a structured evidentiary procedure, not a general opinion poll on innovation. For each relevant subpopulation, data on benefit and harm are compared. If the evidence for a given group cannot be related to the defined comparator therapy, the additional benefit for that group may be considered unproven, even though marketing authorization exists for the indication. The authorized population and the assessed population may therefore differ in their practical significance.
Publication of the assessment also opens the commenting phase. Companies, professional medical societies, medical experts, and other entitled parties may comment on the data and the interpretation of the results. The resolution takes into account both the written submissions and the oral hearing. For dossier work, it is therefore important to maintain a clear distinction between evidence already submitted, information submitted subsequently, and the argumentative framing provided during the commenting procedure.
For operational planning, the distinction between the assessment report and the final resolution is also significant. Only the resolution contains the G-BA’s binding determination with consequences for reimbursement.
The timeline makes robust documentation prior to market entry essential. It is not the resolution itself, but the timely availability of the dossier within the statutory deadline, that determines whether the data can be considered in the intended procedure.
Relevance for clinical trials
For a development programme, the early benefit assessment is particularly critical when the pivotal trial relies on a control arm that differs from the later appropriate comparator therapy. Teams need an early evidence strategy for the German subpopulations, patient-relevant endpoints, and the presentation of treatment pathways. Scientific advice from the G-BA can address requirements for documentation, studies, and comparator therapy ahead of Phase III planning.
Full-service CROs such as Mediconomics support dossier planning, the consolidation of clinical study reports, and the creation of traceable modules on additional benefit. They coordinate regulatory affairs, medical writing, biostatistics, and data management, ensuring that analyses addressing German-specific questions, tables, and study references are delivered consistently and on schedule.
Frequently Asked Questions (FAQ)
Who makes the resolution on the early benefit assessment?
The Federal Joint Committee (G-BA) issues the resolution; it may commission IQWiG or third parties for the technical assessment.
Is every new medicinal product compared against placebo?
No. The decisive factor is generally the appropriate comparator therapy, which is intended to reflect the German care situation for the specific question at hand.
Can the resolution differ between patient groups?
Yes. If evidence or the treatment situation differs between groups, the G-BA may determine the additional benefit separately for each group.
Regulatory References
- Paragraf 35a SGB V – governs the benefit assessment of new active substances and the dossier procedure.
- Ordinance on the Benefit Assessment of Medicinal Products (AM-NutzenV) – specifies the content and conduct of the benefit assessment.
- G-BA Rules of Procedure, Chapter 5 – governs the procedure for the benefit assessment of medicinal products.
- Pharmaceuticals Directive, Annex XII – contains the G-BA’s resolutions on benefit assessment.